As leading pharmaceutical companies continue to identify highly potent (HIPO) and cytotoxic compounds as drug candidates to address critical healthcare needs, it has become a necessity to establish strong partnerships with suppliers that have the capabilities, regulatory infrastructure and experience to handle this special class of compounds.
Cambrex has emerged as a leading supplier of contract development and manufacturing services for HIPO and cytotoxic compounds with fully integrated development programs. Cambrex facilities in North Brunswick, NJ and Charles City, IA regularly handle potent compounds and generate toxicology lot quantities through full scale commercial quantities of HIPO and cytotoxic APIs.
Cambrex began manufacturing potent compounds in 1999 with the construction of a three story 2,380 sq. ft. HIPO production facility in Iowa. More recently, kilo-lab scale isolators were added to the Cambrex sites in New Jersey and Iowa. Further expansion is in the planning stages.
|
